类风湿关节炎患者接受b/tsDMARDs治疗时预防肺孢子菌肺炎:FIRST注册研究3787例分析
基于FIRST注册研究中3787例接受b/tsDMARDs治疗的类风湿关节炎患者,研究描述了预防肺孢子菌肺炎(PCP)的方案。实施策略性预防后,PCP发生率从0.51/100人年降至0.21/100人年(风险比=0.42)。SMX-TMP联合预防效果优于喷他脒吸入(P<0.0001)。
要点
- 策略性PCP预防使RA患者PCP发生率从0.51/100人年降至0.21/100人年(风险比=0.42)
- SMX-TMP联合预防PCP效果优于喷他脒吸入(P<0.0001)
- 高龄、高BMI、合并肺部疾病、低淋巴细胞计数和低血清IgG水平增加PCP风险
核心结论
- 研究明确了接受b/tsDMARDs治疗的RA患者发生PCP的危险因素,并定义了对PCP有效预防的标准。
- 策略性PCP预防可降低PCP发生率,SMX-TMP联合预防效果优于喷他脒吸入。
研究设计与样本
- 研究基于FIRST注册中心的3787例RA患者,分为队列1(n=807,根据医生评估在新开始或切换b/tsDMARDs时需要PCP预防)和队列2(n=2980,接受策略性PCP预防)。
- 研究调查了PCP的发生率和危险因素。
主要发现
- 引入策略性PCP预防后,PCP发生率从0.51/100人年降至0.21/100人年(风险比=0.42)。
- SMX-TMP联合预防PCP的效果优于喷他脒吸入(P<0.0001)。
- 预防率随时间推移增加,尽管平均SMX-TMP剂量和PCP发生率下降。
- 对两组中929例未接受预防的患者亚组分析显示,高龄、高BMI、合并肺部疾病、低淋巴细胞计数和低血清IgG水平增加PCP风险。
关键数值与推荐
- PCP发生率从0.51/100人年降至0.21/100人年(风险比=0.42)。
- SMX-TMP联合预防优于喷他脒吸入(P<0.0001)。
- 未接受预防患者中PCP预测模型在未用糖皮质激素者AUC=0.910,在用糖皮质激素者AUC=0.746。
临床怎么用
- 对接受b/tsDMARDs治疗的RA患者,应根据医生评估进行PCP预防,优先选择SMX-TMP联合方案。
- 应关注高龄、高BMI、合并肺部疾病、低淋巴细胞计数和低血清IgG水平等高危因素,个体化决定预防策略。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: The use of biologic and targeted synthetic (b/ts) DMARDs in the treatment of RA is increasing. Therefore, prevention of b/tsDMARDs-induced infection is important. Here we describe a prophylaxis protocol for preventing pneumocystis pneumonia (PCP) in RA patients treated with b/tsDMARDs. METHODS: The study subjects were 3787 RA patients from the FIRST registry. They were divided into cohort 1 (n = 807, requiring prophylaxis against PCP based on physicians' assessment at the point of new treatment with or switch to b/tsDMARDs) and cohort 2 (n = 2980, receiving strategic PCP prophylaxis). The incidence and risk factors for PCP were investigated. RESULTS: Twenty-six PCP cases were observed throughout the study. After the introduction of strategic PCP prophylaxis, PCP incidence diminished from 0.51/100 person-years (PYs) to 0.21/100 PYs (risk ratio = 0.42). Sulfamethoxazole and trimethoprim in combination (SMX-TMP) showed greater efficacy in the prevention of PCP than pentamidine inhalation (P <0.0001). The prophylaxis rate increased chronologically despite the falls in the average SMX-TMP dose and in the incidence of PCP. Subanalysis of the data for 929 patients from both groups who did not receive prophylaxis showed that old age, high BMI, coexisting lung diseases, low lymphocyte count, and low serum IgG levels increased the risk of PCP development. Development of PCP could be predicted (using an equation based on these variables) in patients not treated with glucocorticoids [area under the curve (AUC) = 0.910)], but less accurately in those on glucocorticoids (AUC = 0.746). CONCLUSIONS: Our study clarified the risk factors for PCP in RA patients on b/tsDMARDs treatment and highlighted and defined the criteria for effective prophylaxis against PCP.
引用
- Sonomoto K, Tanaka H, Nguyen TM, et al. Prophylaxis against pneumocystis pneumonia in rheumatoid arthritis patients treated with b/tsDMARDs: insights from 3787 cases in the FIRST registry. Rheumatology (Oxford). 2022. PMID: 34382090. doi:10.1093/rheumatology/keab647
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。